文献速递系统性红斑狼疮其他结缔组织病

伏环孢素与血压变化:真实世界数据分析

Voclosporin and Changes in Blood Pressure: An Analysis of Real-World Data.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2026-05-18

本研究利用美国电子健康记录数据,分析287例接受伏环孢素治疗的狼疮肾炎患者血压变化。结果显示60.3%患者收缩压出现最小临床重要升高,中位时间90天;60.6%患者舒张压出现最小临床重要升高,中位时间88天。基线血压正常者首月收缩压平均升高13.7 mmHg,提示可能需要更强化血压管理。

要点

  • 真实世界中伏环孢素治疗后约60%患者出现血压最小临床重要升高。
  • 收缩压升高中位时间90天,舒张压升高中位时间88天。
  • 基线血压正常者首月收缩压平均升高13.7 mmHg。

核心结论

  • 真实世界数据显示伏环孢素治疗狼疮肾炎后常见血压升高,可能需要更强化血压管理。

研究设计与样本

  • 基于美国诊所电子健康记录数据的回顾性分析,纳入287例接受伏环孢素处方的患者。

主要发现

  • 287例患者平均年龄41.4岁,83.6%为女性,平均基线血压126/79 mmHg。
  • 60.3%患者收缩压出现最小临床重要升高(10 mmHg),中位时间90天(95%CI 70-102)。
  • 60.6%患者舒张压出现最小临床重要升高(5 mmHg),中位时间88天(95%CI 72-111)。
  • 基线血压正常者首月收缩压/舒张压平均变化为13.7/6.0 mmHg。
  • 基线血压升高者首月收缩压/舒张压平均变化为2.7/-0.6 mmHg,基线高血压者為7.9/-7.3 mmHg。

关键数值与推荐

  • 收缩压最小临床重要升高定义为10 mmHg,舒张压定义为5 mmHg。
  • 基线血压分层:正常(收缩压<130且舒张压<80 mmHg)、升高(收缩压130-164或舒张压80-104 mmHg且非高)、高(收缩压≥165或舒张压≥105 mmHg)。

临床怎么用

  • 接受伏环孢素治疗的狼疮肾炎患者应加强血压监测,尤其基线血压正常者。

局限性

  • 结果可能受血压管理强度差异及美国患者心血管危险因素患病率较高影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hypertension was common in randomized controlled trials of voclosporin, an oral calcineurin inhibitor approved in 2021 to treat lupus nephritis (LN); however, increases in blood pressure (BP) diminished after four weeks. Here, we characterize BP changes in real-world data. METHODS: We used electronic health record data from US practices. We calculated time from first voclosporin prescription to a minimum clinically important increase (MCID) in systolic (10 mm Hg) or diastolic (5 mm Hg) BP and the mean change in BP between baseline and windows of 0 to 1, 1 to 2, 2 to 3, 3 to 6, 6 to 9, and 9 to 12 months after starting treatment. Analyses were stratified by baseline BP as normal (<130 mm Hg systolic and <80 mm Hg diastolic), elevated (130-164 mm Hg systolic or 80-104 mm Hg diastolic and not high), or high (≥165 mm Hg systolic or ≥105 mm Hg diastolic). RESULTS: Among 287 patients (mean age 41.4 years; 83.6% women; 32.1% Black, 24.0% White, 17.1% Hispanic, and 5.6% Asian), mean baseline BP was 126/79 (SD 16/11) mm Hg. Overall, 60.3% experienced a systolic MCID within a median of 90 (95% confidence interval [CI] 70-102) days and 60.6% experienced a diastolic MCID within a median of 88 days (95% CI 72-111). Mean BP changes in the first month were 13.7 (±18.6)/6.0 (±13.8), 2.7 (±18.8)/-0.6 (±11.2), and 7.9 (±17.8)/-7.3 (±16.5) mm Hg for those with normal, elevated, and high BP at baseline. CONCLUSION: Our results may differ because of differences in the intensity of BP management or the higher prevalence of cardiovascular risk factors in US patients. More intensive BP management with voclosporin treatment for LN might be warranted.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Roberts ET, Schmajuk G, Plantinga L, et al. Voclosporin and Changes in Blood Pressure: An Analysis of Real-World Data. Arthritis Care Res (Hoboken). 2026. PMID: 42080617. doi:10.1002/acr.80082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。